Navigation Links
Radioimmunotherapy could extend lives of advanced lymphoma patients

Vancouver, British Columbia A new patient protocol for aggressive and recurrent lymphoma that combines intensive chemotherapy and radioimmunotherapy (RIT) may become the most powerful cancer-killing therapy available, with the hope that patients' lymphoma can be eradicated as they prepare for bone marrow transplant, say researchers at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging. In a study presented at the meeting, survival rates without recurrence improved with the addition of RIT, with some having a 100 percent chance of survival over two years.

"This is a unique randomized study aimed at evaluating a novel treatment approach in patients who have relapsed and aggressive lymphoma with a grave prognosis," said S. Tzila Zwas, MD, professor of nuclear medicine at Sackler School of Medicine, Tel-Aviv University, and Sheba Medical Center in Ramat Gan, Israel. "Currently the best choice for these patients is bone marrow transplantation preceded by high dose chemotherapy with a preparation called BEAM to enhance their response to this engraftment treatment. Here we are studying the effectiveness of a new treatment adding targeted RIT to this standard in order to improve patients' survival."

BEAM is a high-dose chemotherapynamed after its drug constituents carmustine (BiCNU), etoposide, cytarabine (arabinoside) and melphalandeveloped to treat invasive bone marrow cancer. This research compares standard BEAM with BEAM and the addition of RIT with Y-90 ibritumomab tiuxetan (Zevalin), a radionuclide that emits a cancer-killing dose of radiation. This allows doctors to monitor how patients respond to therapy. The new treatment combination is known as Z-BEAM.

In this two-part multicenter prospective study, a total of 43 patients with remaining or relapsed lymphoma were randomized and received one of the two possible treatments prior to bone marrow transplant. Patients who underwent BEAM chemotherapy alone had a 43 percent chance of survival without cancer recurrence, whereas those who received Z-BEAM were shown to have a 64 percent chance of survival, a significant improvement for lymphoma patients. Prognosis varied widely depending on the circumstances of disease and patient age, but those who did not have limiting factors and received Z-BEAM were shown to have a 100 percent chance of survival at two-year follow-up.

"The major significance of this study is in its encouraging overall survival rateresults improved to survival of more than two years in increasing numbers of patients, giving them a better chance overall with very low side effects with Z-BEAM compared to BEAM alone, which appeared to be rather inferior in its results during this study," said Zwas, who also mentioned that further studies are required to expand this regimen into general clinical practice.

Approximately 79,030 people are expected to be diagnosed with lymphoma in 2013. Lymphoma-associated deaths are estimated at 20,200 this year, according to the National Cancer Institute.


Contact: Susan Martonik
Society of Nuclear Medicine

Related medicine news :

1. Novel Liver Stem Cell Model Could Speed Up Process for Developing New Drugs
2. RSNA: ‘Heading’ a Soccer Ball Could Lead to Brain Injury
3. Heading a soccer ball could lead to brain injury
4. Reducing Unnecessary and High-dose Pediatric CT Scans Could Cut Associated Cancers by 62 Percent
5. Woman Who Let Powerball Winner Cut in Line Could Still Live Life of Affordable Luxury with a New Bathroom Remodel
6. New Report: Using Pharmacy Networks in Medicaid Could Save New York an Additional $3.7 Billion
7. School-located vaccination programs could reduce flu cases and deaths among children
8. Bladder cancer recurrence and mortality could decline with better treatment compliance
9. Neighborhood features could prevent obesity
10. Technique could identify patients at high risk of stroke or brain hemorrhage
11. New method to test breast lesions could better detect cancer, save money by reducing repeat biopsies
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in ... on several models of traditional and far-infrared saunas. , For traditional saunas, ... the most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic ...
(Date:11/25/2015)... Cokato, MN (PRWEB) , ... November 25, 2015 ... ... manufacturer, launched offering factory direct sauna parts and accessories. , Sauna accessories ... representative of the bather’s style and personality. From basic styles for the purist ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, ... Union (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil ... for the opening of the 5th African Network for Drugs and Diagnostics Innovation, ...
(Date:11/25/2015)... Friendswood, TX (PRWEB) , ... November 25, 2015 , ... ... through the companies’ “ Two Organizations, One Beat ” campaign. The partnership between the ... its services to aid in MAP International’s cause. , MAP International was founded in ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
Breaking Medicine Technology: